The PCSK9 inhibitor evolocumab (Repatha) got the FDA's blessing for cardiovascular protection, with or without a history of cardiovascular disease (CVD). Evolocumab is now indicated for the wider pool ...

In patients with an atherosclerotic CVD event or at intermediate to high risk for one who were on statin therapy, a novel ...

Immune checkpoint therapy, particularly anti-PD-1/PD-L1 immunotherapy, have achieved significant results in the treatment of various tumors. However, most cancer patients show a low response rate to ...

Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

The FDA approved lerodalcibep (Lerochol) injections for the treatment of elevated LDL cholesterol in adults, maker LIB Therapeutics announced. A third-generation PCSK9 inhibitor, lerodalcibep is ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Please provide your email address to receive an email when new articles are posted on . PCSK9 inhibitors lower cholesterol and risk for heart disease, but barriers to access exist. A ...

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density ...

It cannot be denied that statins have revolutionized how we treat and prevent coronary heart disease. But there are both external and intrinsic reasons why some patients do not respond adequately to ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, lipid-lowering drugs, were associated with a 22% lower risk for nonmelanoma skin cancer (NMSC) in patients with atherosclerotic ...